South Africa

The South African Health Products Regulatory Authority (SAHPRA) is the primary national regulatory body responsible for the oversight of medicines, medical devices, in vitro diagnostics, complementary medicines, and biological products in South Africa. Established under the Medicines and Related Substances Act 101 of 1965, as fundamentally amended by the Medicines and Related Substances Amendment Act 14 of 2015, SAHPRA replaced the former Medicines Control Council (MCC) and became fully operational as an independent entity in 2018. All health products intended for sale or distribution in South Africa must be registered with SAHPRA prior to market entry, unless explicitly exempted. The approval process involves a structured dossier review covering quality, safety, and efficacy data, with medical devices and in vitro diagnostics subject to a risk-based classification system aligned with international frameworks such as those of the Global Harmonization Task Force (GHTF) and the International Medical Device Regulators Forum (IMDRF).

SAHPRA accepts submissions formatted according to the Common Technical Document (CTD) structure for pharmaceuticals and biological products, and aligns its device and diagnostic requirements with internationally recognized standards including ISO 13485 and IMDRF guidance documents. Applicants must appoint a locally registered responsible pharmacist or a South African-based legal representative as part of the submission process. SAHPRA has introduced several reforms in recent years aimed at reducing registration backlogs and accelerating access to innovative products, including a Risk-Based Approval Pathway, reliance mechanisms that recognize approvals from stringent regulatory authorities such as the EMA, US FDA, Health Canada, and TGA Australia, and an expedited review pathway for priority medicines. Digital health products and software as a medical device (SaMD) are increasingly subject to regulatory scrutiny under the device framework, with SAHPRA developing specific guidance in this area. A backlog of legacy product registrations has historically extended effective timelines well beyond the statutory targets, though ongoing reforms are progressively addressing this challenge.

Public sector procurement of health products in South Africa is primarily coordinated through the National Department of Health (NDoH) and executed via the State Tender Board framework, governed by the Public Finance Management Act (PFMA) and the Preferential Procurement Policy Framework Act (PPPFA). The NDoH centrally negotiates and awards national contracts for essential medicines, vaccines, and priority health commodities through competitive tender processes managed by the National Treasury and the Central Procurement Administration. Each of the nine provincial health departments also retains procurement autonomy for certain product categories and supplementary supply needs, creating a dual-layer public procurement environment. Products must generally hold a valid SAHPRA registration to be considered for public tender inclusion, and pricing for medicines in the public sector is influenced by the National Department of Health pricing regulations and international benchmarking tools such as the Pharmaceutical Reference Price List. The Essential Medicines List (EML) and the Standard Treatment Guidelines (STGs) serve as critical gatekeeping frameworks that determine which products are considered for public formulary inclusion and tender eligibility.

The private sector in South Africa represents a substantial and commercially significant channel, operating through large hospital groups such as Netcare, Life Healthcare, and Mediclinic, as well as retail pharmacy chains and independent dispensers. Private sector procurement is largely decentralized, with buying decisions influenced by formulary listing with major medical schemes and managed care organizations operating under the Medical Schemes Act 131 of 1998. The Council for Medical Schemes (CMS) regulates medical scheme benefits, and Prescribed Minimum Benefits (PMBs) shape reimbursement priorities. South Africa is also a significant recipient of donor-funded health commodity procurement, with the Global Fund to Fight AIDS, Tuberculosis and Malaria, PEPFAR through USAID, and Gavi, the Vaccine Alliance, all contributing to procurement volumes particularly in HIV, tuberculosis, malaria, and immunization programs. These donor channels frequently procure through international procurement agents including UNICEF Supply Division and the USAID Supply Chain Management System (SCMS), with products required to meet SAHPRA registration requirements or qualify under specific exemptions. South Africa's Broad-Based Black Economic Empowerment (B-BBEE) policy and local content preferences under the PPPFA create incentives for local manufacturing and supply partnerships, and the government has signaled ambitions to expand domestic pharmaceutical and medical device manufacturing capacity as part of its post-pandemic industrial policy agenda.